sesamoside: an iridoid glucoside; from Phlomis mongolica Turz; RN given refers to (1aR-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Phlomis | genus | A plant genus of the family LAMIACEAE that contains phlorigidosides, iridoid glucosides and megastigmane glycosides.[MeSH] | Lamiaceae | The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH] |
| Phlomis mongolica | species | [no description available] | Lamiaceae | The mint plant family. They are characteristically aromatic, and many of them are cultivated for their oils. Most have square stems, opposite leaves, and two-lipped, open-mouthed, tubular corollas (united petals), with five-lobed, bell-like calyxes (united sepals).[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 3082856 |
| CHEMBL ID | 2048637 |
| MeSH ID | M0261070 |
| Synonym |
|---|
| 117479-87-5 |
| oxireno(4,5)cyclopenta(1,2-c)pyran-5-carboxylic acid, 2-(beta-d-glucopyranosyloxy)-1a,1b,2,5a,6,6a-hexahydro-5a,6-dihydroxy-1a-methyl-, methyl ester. (1ar-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))- |
| 2-(beta-d-glucopyranosyloxy)-1a,1b,2,5a,6,6a-hexahydro-5a,6-dihydroxy-1a-methyloxireno(4,5)cyclopenta(1,2-c)pyran-5-carboxylic acid methyl ester. (1ar-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha))- |
| sesamoside |
| CHEMBL2048637 |
| S9405 |
| 3-hydroxyhexadecanoicacidmethylester |
| DTXSID00922430 |
| methyl 2-(hexopyranosyloxy)-5a,6-dihydroxy-1a-methyl-1a,1b,2,5a,6,6a-hexahydrooxireno[4,5]cyclopenta[1,2-c]pyran-5-carboxylate |
| AKOS032946156 |
| HY-N0412 |
| methyl (1s,2r,4s,5r,6r,10s)-5,6-dihydroxy-2-methyl-10-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,9-dioxatricyclo[4.4.0.02,4]dec-7-ene-7-carboxylate |
| mfcd20274707 |
| CCG-268887 |
| CS-0008942 |
| MS-27371 |
| oxireno[4,5]cyclopenta[1,2-c]pyran-5-carboxylic acid, 2-(beta-d-glucopyranosyloxy)-1a,1b,2,5a,6,6a-hexahydro-5a,6-dihydroxy-1a-methyl-, methyl ester, (1ar,1bs,2s,5ar,6r,6as)- |
| Q2S45L3ZVB |
| oxireno[4,5]cyclopenta[1,2-c]pyran-5-carboxylic acid, 2-(beta-d-glucopyranosyloxy)-1a,1b,2,5a,6,6a-hexahydro-5a,6-dihydroxy-1a-methyl-, methyl ester, [1ar-(1aalpha,1bbeta,2beta,5abeta,6beta,6aalpha)]- |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID671429 | Inhibition of LPS-induced NF-KB transcriptional activity expressed in HEK-293 cells at 100 ug/ml after 4 hrs by luciferase reporter gene assay relative to LPS-treated group | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13 | Iridoid glucosides and a C₁₃-norisoprenoid from Lamiophlomis rotata and their effects on NF-κB activation. |
| AID671428 | Inhibition of LPS-induced NF-KB transcriptional activity expressed in HEK-293 cells at 10 ug/ml after 4 hrs by luciferase reporter gene assay relative to LPS-treated group | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13 | Iridoid glucosides and a C₁₃-norisoprenoid from Lamiophlomis rotata and their effects on NF-κB activation. |
| AID671427 | Inhibition of LPS-induced NF-KB transcriptional activity expressed in HEK-293 cells at 1 ug/ml after 4 hrs by luciferase reporter gene assay relative to LPS-treated group | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13 | Iridoid glucosides and a C₁₃-norisoprenoid from Lamiophlomis rotata and their effects on NF-κB activation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||